A surgeon in Jacksonville, Florida just performed brain surgery on a patient in Dundee, Scotland. They've never been in the same room.
Dr. Ricardo Hanel worked a robotic system that mirrored his hand movements in real time across the Atlantic, clearing a blocked blood vessel in the brain with the precision of in-person surgery. It's the first transatlantic thrombectomy—the gold-standard treatment for the most severe strokes—ever attempted.
The technology comes from Sentante, a Lithuanian MedTech company that built something unusual: a robot that doesn't feel like a robot. Instead of joysticks or screens, the surgeon's hands control guidewires and catheters through the same sensory feedback they'd feel in the operating room. The system captures force and resistance in real time, sending it back through the surgeon's fingertips. "As a neurointerventionist, it is remarkable to feel the same fine control and resistance through a robotic interface as during a live procedure," said Professor Iris Grunwald, who led the Dundee team.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxWhy this matters now
Stroke is brutal partly because of time. Every six minutes a patient waits for treatment, their chances of a good outcome drop by 1%. In Scotland, only 212 thrombectomies were performed in 2024—about 2.2% of ischemic stroke patients who needed them. Most patients never reach a specialist center in time. The UK spends £26 billion annually treating stroke and its aftermath.
Remote robotic surgery collapses that geography problem. Instead of transporting a patient hours away from their nearest hospital, the specialist comes to them—instantly, across any distance. Grunwald put it plainly: "By the time patients reach a specialist centre, there's often no brain left to save."
Sentante's system has already caught the FDA's attention. It received Breakthrough Device Designation, which accelerates the regulatory pathway toward clinical use. The company is moving toward approval, which means this test across the Atlantic wasn't a one-off demonstration—it was a proof that the next phase of stroke care is technically possible.
The real test comes next: whether hospitals will adopt it, whether insurers will fund it, whether the technology works as reliably in routine practice as it did in this controlled experiment. But the barrier that seemed permanent—the need for a world-class neurointerventionist to be physically present—just got removed.
